The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new advances. Speaking from the 1st European Myeloma Network Meeting (EMN) in Turin, Italy, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, describes some of the work currently being performed regarding predictive biomarkers for kinase inhibitor treatment response. Prof. Malavasi also mentions daratumumab and its synergistic action when given to patients in combination with novel kinase inhibitors.
